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(57) ABSTRACT 
A solid-phase immunoassay for 6-keto-Prostaglandin Fla, 
the stable hydrolysis product of prostacyclin (Prostaglandin 
I2) is disclosed. Prostacyclin, a potent vasodilator With anti 
platelet and anti-proliferative properties is an effective treat 
ment for primary pulmonary hypertension and pulmonary 
arterial hypertension associated With scleroderma and scle 
roderma-like syndrome. Levels of 6-keto-Prostaglandin F la 
can be directly correlated With levels of prostacyclin. There 
fore, 6-keto-Prostaglandin F la has become the indicator of 
choice to measure prostacyclin levels. The single step immu 
noassay for 6-keto-Prostaglandin Fla uses the biolumines 
cent protein, aequorin as a label. Analyte-label conjugates 
Were constructed by linking the carboxyl group of 6-keto 
Prostaglandin Fla and lysine residues of aequorin by chemi 
cal conjugation methods. The binding properties of 6-keto 
Prostaglandin Fla toWards its antibody and the 
bioluminescent properties of aequorin are retained in the 
conjugate. The concentration of 6-keto-Prostaglandin Fla 
after extraction from plasma shoWs good correlation With the 
concentration of 6-keto-Prostaglandin Fla obtained Without 
prior extraction of the same plasma sample. The assay alloWs 
the measurement of 6-keto-Prostaglandin Fla directly in 
plasma Without any pre-treatment of the samples, Which 
results in a much simpler method With a faster assay time. 
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METHOD AND KIT FOR DETERMINATION 
OF PROSTACYCLIN IN PLASMA 
RELATED APPLICATIONS 
This application claims the bene?t of provisional applica 
tion 60/396,122, ?led Jul. 17, 2002, Which is incorporated 
herein in its entirety. 
This invention Was made With government support pro 
vided by The National Institutes of Health. 
FIELD OF THE INVENTION 
The invention relates generally to methods of determining 
the level of pro stacyclin in plasma using the conjugates. More 
particularly, the invention relates to a single step immunoas 
say for detection of the level of 6-keto-prostaglandin F1, 
Which directly correlates to the level of prostacyclin in 
plasma. 
BACKGROUND OF THE INVENTION 
Primary Pulmonary Hypertension (PPH) is a rare disease 
of the pulmonary vasculature, resulting in abnormally high 
pressure in the pulmonary artery, right ventricular failure, and 
death. While the pathogenesis of PPH is not clearly under 
stood, the increased pulmonary vascular resistance observed 
is attributed to three main factors: 1) vasoconstriction, 2) 
thickening of the vessel Wall due to vascular remodeling, and 
3) in situ thrombosis. (Archer, S., Rich, S. Circulation 2000, 
102, 2781-2791; Rich, S. Curr. Treat Options. Cardiovasc. 
Med. 2000, 2, 135-140). There is no cure for PPH and the 
treatment options are limited. (N aeije, R.,Vachiery, J. L. Clin. 
Chest Med. 2001, 22, 517-527). The survival rate is less than 
a year in patients presented With NeWYork Heart Association 
Functional Class IV symptoms. Although lung transplanta 
tion is a possible treatment option, there are obvious draW 
backs such as shortage of donor organs and chronic rejection 
as Well as the possibility of infection. (Franke, U., Wiebe, K., 
Harringer, W., Franke, T., WittWer, T., Wahlers, T., Haverich, 
A. Eur J. Cardiothorac. Surg. 2000, 18, 447-452). Long term 
intravenous treatment With epopro stenol (also knoWn as pros 
tacyclin or PGI2) has greatly increased the survival rate. 
Prostacyclin or PGI2 (Prostaglandin I2) is a major 
cyclooxygenase metabolite of arachidonic acid, and is mainly 
produced by vascular endothelial cells. Prostacyclin is a pros 
taglandin, Which occurs along With other eicosanoids like 
thromboxanes and leukotrienes. Prostacyclin is a potent 
vasodilator With platelet-inhibitory, anti-proliferative and 
?brinolytic activities. (Moncada, S., Vane, J. R. Pharmaco 
logical Rev. 1979, 30). 
The exact levels of prostacyclin in human plasma are 
unknoWn, hoWever like mo st eicosanoids it occurs in very loW 
amounts (pg/mL). Thromboxane B2 (metabolite of throm 
boxane A2, a vasoconstrictor) and its metabolites occur in 
very loW amounts like 1-10 pg/mL in plasma. Leukotrienes 
generally function as vasoconstrictors and bronchoconstric 
tors and occur in varying amounts in plasma and urine. Leu 
kotriene B4 occurs betWeen 50 pg/mL-50 ng/mL, leukotriene 
E4 occurs betWeen 80 pg/mL-1000 ng/mg of creatinine. Pros 
taglandin F20‘ concentrations are found betWeen 10 pg/mL 
100 pg/mL, prostaglandin D2 is generally found at 5 pg/mL 
500 pg/mL, and prostaglandin Fla occurs at 1 ng/mL-100 
ng/mL. 
Currently intravenous epoprostenol is indicated for the 
chronic treatment of primary pulmonary hypertension (PPH) 
in NeW York Heart Association (NYHA) functional Class III 
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and Class IV patients Who do not respond to conventional 
therapy. (Krishnan, U. Indian J. Pediatn 2000, 67, 523-527; 
Nauser, T. D., Stites, S. W. Am. Fam. Physician 2001, 63, 
1789-1798). There is no set dose of prostacyclin for PPH and 
the starting dose varies betWeen 4-8 ng/kg/min. Following the 
initiation of intravenous prostacyclin, most patients require 
an automatic dose increase of 2 ng/kg/min every tWo Weeks 
until the rate of administration reaches 20 ng/kg/min. Further 
dose increase of 0.5 to 1 ng/kg/min per Week is needed only 
upon the return of symptoms. Common side effects of intra 
venous prostacyclin include ?ushing, muscle pain, and 
abdominal cramps and these symptoms are not necessarily 
dose dependent. Thus, a method to quantify and correlate the 
plasma levels of prostacyclin With the onset of the untoWard 
side effects or functional improvement Would be useful in 
determining the optimal level of plasma prostacyclin for an 
individual patient. 
A method to quantify the plasma levels of prostacyclin 
Would be useful in determining the optimal level of plasma 
prostacyclin for an individual patient. Prostacyclin is very 
unstable With a half-life of only 60 minutes in plasma and 2-3 
minutes in buffer. The immediate and stable product of 
hydrolysis of prostacyclin, 6-Keto-Prostaglandin Fla 
(6-keto-PGFla), is quanti?able and can be used as a surrogate 
marker of the level of plasma prostacyclin. The detection 
method for prostacyclin or its breakdoWn product has to be 
extremely sensitive and accurate since either molecule is 
present in very loW amounts (pg/mL) in the body. Moreover, 
the existing methods are time consuming mainly due to the 
necessity to extract 6-keto-PGF1G from biological samples. 
(Schramm, W., Smith, R. H., Jackson, T. M., Craig, P. A., 
Grates, H. E., and Minton, L. L. Clinical Chem. 1990, 36, 
509-514; Tonai T.,Y., K.,Yano, T., Hayashi,Y.,Yamamoto, S., 
Yamashita, K., and MiyaZaki, H. Biochim. Biophys. Acta 
1985, 836, 335-343). Thus there is a need for a rapid and 
sensitive detection method for prostacyclin. The present 
invention provides a single-step, solid phase immunoassay 
for 6-keto-PGF1a using the bioluminescent protein aequorin. 
SUMMARY OF THE INVENTION 
In one aspect of the invention there is provided an assay for 
determining amount of prostacyclin in a plasma sample com 
prising: 
(1) providing a plasma sample on a surface coated With an 
anti-immunoglobulin antibody; 
(2) incubating the plasma sample With an effective amount 
of an anti-6-keto-PGFla primary antibody, a secondary 
anti-6-keto-PGF1a antibody and 6-keto-PGFla-ae 
quorin conjugate; 
(3) removing any unbound primary antibody and 6-keto 
PGFla-aequorin conjugate folloWing incubation; and 
(4) measuring and correlating light intensity of the plasma 
sample With amount of prostacylin Within the plasma 
sample. 
In a preferred embodiment of this aspect of the invention, 
the assay is performed in a microtiter format. Preferably, the 
secondary antibody is coated onto a surface and exposed to 
the plasma sample, primary antibody and 6-keto-PGFl-ae 
quorin conjugate. 
In another aspect of the invention there is provided a 
method of determining an appropriate dose of prostaglandin 
for the treatment of primary pulmonary hypertension in a 
patient comprising 
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(1) providing a plasma sample from the patient; 
(2) incubating the plasma sample With an effective amount 
of anti-6-keto-PGF 1 primary antibody, a secondary anti 
6-keto-PGFl antibody, a 6-keto-PGF1-aequorin conju 
gate; 
(3) removing any unbound primary antibody and conjugate 
from the plasma sample folloWing incubation; 
(4) measuring and correlating amount of detected 6-keto 
PGFl With the appropriate dosage of prostaglandin for 
the patient. 
In another aspect of the invention there is provide a kit for 
measuring amount of prostacyclin in plasma comprising 
(1) a 6-keto-PGF1-aequorin conjugate; 
(2) an anti-6-keto-PGFl primary antibody; and 
(3) a secondary anti-6-keto-PGFl primary antibody coated 
plate. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shoWs the binder dilution curves obtained by incu 
bating a volume of 100 ML of varying concentrations of 
6-keto-PGF1a antibody and 6-keto-PGFla-aequorin conju 
gates With secondary antibody coated plates. Data are an 
average of three pointszthe standard deviation. (I) 1 :50 Con 
jugate, (O) 1:100 Conjugate, (Q) 1:500 Conjugate. 
FIG. 2 shoWs the dose-response curves for 6-keto-PGF1a 
generated by incubating varying concentrations of 6-keto 
PGFla With 1><10_lo M conjugate and (I) 1:5000 dilution of 
6-keto-PGF1a antibody, or (Q) 1:50,000 dilution of 6-keto 
PGFla antibody and 1:10,000 dilution of 6-keto-PGF1a anti 
body With ( )1><10_9 M 6-keto-PGFla-AEQ conjugate. Data 
are an average of three pointsithe standard deviation. 
FIG. 3 is a dose-response curve for 6-keto-PGF la obtained 
by incubating 100 ML of 6-keto-PGFla antibody, 50 ML vol 
ume of 1x10“10 M 6-keto-PGFla-AEQ conjugate and vary 
ing concentrations of 6-keto-PGFla. Data are an average of 
three pointszthe standard deviation. 
FIG. 4 is a dose-response curve for 6-keto-PGF1a in 
plasma of a healthy person obtained by incubating 100 ML of 
6-keto-PGF1a antibody, 50 ML volume of1><10_1O M 6-keto 
PGF m-AEQ conjugate and varying concentrations of 6-keto 
PGFla in 1:200 diluted plasma. Data are an average of three 
pointszthe standard deviation. 
DETAILED DESCRIPTION OF THE INVENTION 
Various types of detection methods have been reported in 
the literature for prostacyclin using its stable hydrolysis prod 
uct, 6-keto-PGF 1w as a measure of prostacyclin levels. For 
example, the methods include radioimmunoassays, enZyme 
immunoassays, and detection using gas liquid chromatogra 
phy-mass spectrometry (GLC-MS) or gas chromatography 
selective ion monitoring (GC-SIM). (Tonai T., Y., K., Yano, 
T., Hayashi, Y., Yamamoto, S., Yamashita, K., and MiyaZaki, 
H. Biochim. Biophys. Acta 1985, 836, 335-343; Fischer C, M. 
C. Biomed. Mass Spectrom. 1985, 12, 399404; and Maclouf, 
1., Pradel, M., Pradelles, P. and Dray, F. Biochim. Biophys. 
Acta 1976, 431, 139-146. Radioimmunoassay is a highly 
sensitive method but it has the disadvantages associated With 
the use of radioactivity. Moreover, all the immunoassays or 
chromatographic techniques reported for 6-keto-PGF 1w 
require extraction of 6-keto-PGFla from plasma or plasma 
samples making the process laborious and time consuming. 
(Tonai T., Y., K., Yano, T., Hayashi, Y., Yamamoto, S., 
Yamashita, K., and MiyaZaki, H. Biochim. Biophys. Acta 
1985, 836, 335-343; Fischer C, M. C. Biomed. Mass Spec 
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trom. 1985, 12, 399-404; and Maclouf, 1., Pradel, M., 
Pradelles, P. and Dray, F. Biochim. Biophys. Acta 1976, 431, 
139-146. 
In contrast, the present invention provides a sensitive biolu 
minescent immunoassay for 6-keto-PGF la Where the plasma 
samples are analyZed directly Without requiring the extrac 
tion of 6-keto-PGFla from plasma. This results in a simpler, 
faster method for detection of this analyte in plasma samples. 
The present assay for 6-keto-PGFla is preferably performed 
in a microtiter plate format using the photoprotein aequorin as 
the label. Colorimetric and ?uorescent assays could possibly 
suffer from background interference limiting their use in 
direct plasma analysis. Aequorin, hoWever, being a biolumi 
nescent label has virtually no background associated With 
aequorin is a highly sensitive label. 
Aequorin has proved to be a highly sensitive label in the 
development of binding assays for the determination of large 
and small biomolecules. (Zenno, S., Inouye, S. Biochem. 
Biophys. Res. Commun. 1990, 171, 169-174; Christopoulos, 
T. K., and Galvan, B. Anal. Chem. 1996, 68, 3545-3550; 
Zatta, P. F. J. Biochem. Biophys. Methods 1996, 32, 7-13; 
Stults, N. L., Stocks, N. F., Riviera H., Gray 1., McCann R. O., 
O’Kane D., Cummings R. D., Cormier M. 1., and Smith D. F. 
Biochemistry 1991,31, 1433-1438). The bioluminescent pro 
tein aequorin is native to the jelly?sh Aequorea Victoria. 
Aequorin is a bioluminescent photoprotein that is composed 
of an apoprotein (apoaequorin, 189 amino acid residues), a 
chromophoric unit (coelenteraZine) and molecular oxygen. 
Aequorin has three Ca2+ binding sites. When Ca2+ binds to 
aequorin, it undergoes a conformational change that results in 
the oxidation of coelenteraZine to coelenteramide and this 
produces CO2 and emits a ?ash of light at 469 nm. The 
bioluminescent signal produced by aequorin has virtually no 
background signal and the quantum e?iciency is betWeen 
1 1-17.5%, alloWing it to be detected doWn to attomole levels. 
(Stults, N. L., Stocks, N. F., Riviera H., Gray 1., McCann R. 
O., O’Kane D., Cummings R. D., Cormier M. 1., and Smith D. 
F. Biochemistry 1991, 31, 1433-1438; Ramanathan, S., 
LeWis, 1. C., Kindy, M. S., and Daunert, S. Anal. Chim. Acta. 
1998, 369, 181-189; Shimomura, O. Biol. Bull. 1995, 189, 
1-5; LeWis, 1. C., LopeZ-Moya, 1. 1., and Daunert S. Biocon 
jugate Chem. 2000, 11, 65-70). 
In the present invention a cysteine-free mutant of aequorin 
is preferred because it shoWs enhanced activity. LeWis, 1. C., 
LopeZ-Moya, 1. 1., and Daunert S. Bioconjugate Chem. 2000, 
11, 65-70, incorporated herein in its entirety. HoWever, any 
suitable aequorin may be used as a label in the present meth 
ods and kits. Recombinant aequorin may be produced and 
puri?ed for use in the present assay for 6-keto-PGFla. For 
example, the compound 6-keto-PGFla may be conjugated to 
pure aequorin by conventional covalent attachment to the free 
amine groups of the lysine residues in aequorin. Aequorin 
contains 15 lysine residues. 
In developing the present assay, the effect of choosing 
different initial ratios of analyte to the apoprotein on the 
bioluminescence properties of the protein, and the binding 
ability of an anti-6-keto-PGF1a antibody Was investigated. 
Further, the effect of an antibody for 6-keto-PGF1a on the 
luminescence signal Was evaluated. Based on the results, the 
sensitive bioluminescent binding assay for 6-keto-PGF1a 
described herein Was developed. The assay Was then further 
optimiZed for detection of the analyte in plasma. Several 
plasma samples from PPH patients Were analyZed by using 
them directly in the assay Without any extraction of 6-keto 
PGFla. 
In the present method, the detection and quanti?cation of 
6-keto-PGF1a directly in a plasma sample Without extraction 
US 7,659,078 B1 
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of the prostaglandin is achieved using a 6-keto-PGFl anti 
body and a 6-keto-PGF-aequorin conjugate. The plasma 
sample may be diluted, for example about 200-fold With an 
appropriate medium, such as deionized Water, and an effec 
tive amount of antibody and prostaglandin-conjugate added. 
An effective amount of antibody to be used in the assay 
dependent upon the particular antibody used and is selected to 
such that the light intensity generated thereWith is su?icient to 
measure a signal above background, While keeping the 
amount of available binding sites to a minimum. In general, 
When the amount of antibody is increased, the sensitivity of 
the assay is improved but the detection limit of the assay is 
compromised. When a more diluted amount of antibody is 
used, the dynamic range is narroWed and sensitivity is 
reduced. 
The amount of 6-keto-PGF-aequorin conjugate used in the 
present assay depends upon the speci?c conjugate used and 
can readily be determined by one of skill in the art. In general, 
the concentration range of conjugate is about 0. l x l 0'10 to 
about 9x10“ 1 0, preferably about 1x10“ 1 O. 
In carrying out the present assay in a microtiter plate for 
mat, a plasma sample is obtained from a patient and applied to 
a surface, such as a surface of a microtiter plate, that has been 
precoated With a secondary antibody. An amount of anti-6 
keto-PGFla primary antibody and anti-6-keto-PGFla-ae 
quorin conjugate is then added to the plasma sample and the 
mixture incubated in the dark for a period of time ranging 
from about 1 to about 3 hours, preferably about 2 hours at 
room temperature. The surface is then Washed to remove 
unbound primary antibody and conjugate, and the light inten 
sity is determined and correlated With the amount of 6-keto 
PGF la present in the sample, Which in turn directly correlates 
With the amount of prostacyclin in the sample. 
The determination of amount of prostacyclin in a sample 
obtained from a patient may then be used to determine the 
appropriate dosage of prostglandin to administer to a patient 
being treated for PPH, for example. 
It has been ob served in the scienti?c literature that the drug, 
Viagra®, available from P?zer Inc. is a potential candidate for 
therapy in patients suffering from PPH. Sayin et al., Can. J. 
Cardiol., 2002, 18(6): 676-678. It has been demonstrated that 
Viagra® acts as an inhibitor of the enZyme, phosphodi 
esterase. Inhibition of this enZyme causes increase in levels of 
cGMP and cAMP, Which control groWth of the smooth 
muscle cell layer that surrounds pulmonary arterioles. Prolif 
eration of these smooth muscle cells has been linked With 
PPH. Prostacylin also acts as a dilator of smooth muscle cells 
by increasing the levels of cyclic nucleotides. Furthermore, it 
has been found that phosphodiesterase inhibitor enhances 
vasodilatory ef?cacy of prostacyclin. Thus, the effects of 
Viagra® therapy on levels of prostacyclin in the blood can be 
determined using the assay for 6-keto-prostaglandin, 
described herein. Also, the appropriate dosage of Viagra® 
can also be determined by application of the assay for 6-keto 
prostaglandin, described herein. 
The present invention also provides unique aequorin 
mutants that are suitable for conjugation to 6-keto protaglan 
din F 1 for use in the above-described as says or for conjugation 
to other biomolecules, such as those suspected of playing a 
pathologicaal role in PPH, e.g., endothelin, angiotensin II, 
vasopressin, and neurotransmitter. These mutant aequorins 
can be conjugated to the desired biomolecule to analyZe the 
role of the biomolecule in PPH, to analyZe the metabolism of 
the biomolecule, to determine any correlation of serum level 
With physiological effect, or for drug design, for example. 
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Similarly, these conjugates can be used in assays to determine 
the effects of the conjugated biomolecule on drug therapy, for 
example 
Aequorin- or mutant aequorin-biomolecule conjugates 
prepared either through non-speci?c, site-speci?c or genetic 
conjugation can be used in the assays of the invention. 
Aequorin mutants Which have a unique cysteine at amino acid 
residue 69, 70, 74 or 76 (described in the examples) have been 
developed. These amino acid residues are close to the sub 
strate-binding site in aequorin and therefore, binding of anti 
body to an analyte attached at any of these sites yields a 
homogeneous change in bioluminescence. Such results Were 
demonstrated With an aequorin-thyroxine conjugate, Where 
the thyroxine is bound to the sulfhydryl of a unique cysteine 
at position 71 of the aequorin molecule. 
The present invention also contemplates kits for measuring 
amount of prostacyclin in a plasma sample. Kits preferably 
contain a primary antibody for 6-keto-PGF1a and a secondary 
antibody and a 6-keto-PGFla-aequorin conjugate. Prefer 
ably, the conjugate is a cysteine-free mutant of aequorin con 
jugated to 6-keto-PGFla. The kit may also include assay 
buffer, deioniZed Water, and/ or microtiter plates or other sur 
faces pre-coated With the secondary antibody or for coating 
With secondary antibody at the time of performing the assay. 
EXAMPLE 1 
Reagents used in the examples herein include: Luria Ber 
tani (LB) broth and agar Were purchased from DIFCO Labo 
ratories (Detroit, Mich.). Sodium dodecyl sulfate (SDS), 
sodium hydroxide, sodium chloride, calcium chloride, 
bovine plasma albumin (B SA), kanamycin, ethylenediamine 
tetra acetic acid (EDTA) disodium salt and 6-keto-Prostag 
landin F la Were obtained from Sigma Laboratories (St. Louis, 
Mo.). N-hydroxysuccinimide (NHS) and l-Ethyl-3-(Dim 
ethylaminopropyl) carbodiimide hydrochloride (EDC) Were 
purchased from Pierce (Rockford, Ill.). HQH, quatemiZed 
polyethyleneimine anion exchanger Was purchased from Per 
Septive Biosystems (Cambridge, Mass.). The anti-6-keto 
Prostaglandin E la antibody and the 96-Well microtiter plates 
coated With anti-sheep-IgG Were purchased from Assay 
Designs Inc. (Ann Arbor, Mich.). Tris (hydroxymethyl) 
amino methane (Tris) Was purchased from Research Organics 
(Cleveland, Ohio). CoelenteraZine Was purchased from Bio 
synth International (Naperville, Ill.). Bradford assay kits 
Were obtained from Bio-Rad Laboratories (Hercules, Calif.). 
Patient samples as Well as control samples Were provided by 
Dr. Michael Poon (Mount Sinai School of Medicine, NY). 
All solutions Were prepared using deioniZed (Milli-Q Water 
Puri?cation System, Millipore, Bedford, Mass.) distilled 
Water. All chemicals Were analytical reagent grade or better, 
With >95% purity and Were used as received. 
Cell cultures Were groWn in an orbital shaker, Form a 
Scienti?c (Marrietta, Ohio) and centrifuged using a Beckman 
J2-MI centrifuge (Palo Alto, Calif.). The fractions Were lyo 
philiZed using a VirTis Bench Top three freeZe dryer (Gar 
diner, N.Y.). Bioluminescence measurements for the assay 
Were made on MLX Microtiter Plate Luminometer Dynex 
(Chantilly, Va.). For all the measurements four replicates 
Were performed and three of the closest Were selected. All 
luminescence intensities reported are the average of three 
replicates, and have been corrected for the contribution of the 
background. 
Expression and Puri?cation of Apoaequorin: The plasmid 
pSDl 10 containing the cysteine free mutant (mutant S) of 
aequorin Was constructed and initially transformed in com 
petent B. sublilis cells. For protocols for the expression and 
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puri?cation of apoaequorin and the conversion of apoae 
quorin to the photoprotein, see Lewis, J. C., LopeZ-Moya, J. 
J ., and Daunert S. Bioconjugale Chem. 2000, 11, 65-70, 
incorporated herein. 
Conjugation of Aequorin to 6-keto-Prostaglandin Fla: A 
volume of 1 mL of 1x10“6 M. aequorin Was allowed to incu 
bate With coelenteraZine for 3 h at 4° C. The N-hydroxysuc 
cinimide ester of 6-keto-Prostaglandin Fla Was prepared by 
reacting With the Water-soluble analog of N-hydroxysuccin 
imide (NHS), sulfo-NHS, and the dehydrating agent EDC. 
Grabarek. Z. a. G., J. Anal. Biochem. 1990, 185. The analyte 
6-keto-Prostaglandin Fla (1 mg/mL) Was alloWed to react 
With ~5 mM sulfo NHS and ~2 mM EDC (?nal concentra 
tions) for 30 minutes at R.T. The reaction Was quenched by 
adding [3-mercaptoethanol to a ?nal concentration of 20 mM. 
This NHS ester of the analyte Was then conjugated to 
aequorin With bound coelenteraZine in three different mole 
ratios, 1:50, 1:200, and 1:500 of aequorin: 6-keto-PGFla The 
conjugates Were passed through a siZe exclusion column in 
order to remove any unconjugated NHS ester of 6-keto 
PGFla and any residual reactants or reducing agent. The 
fractions Were tested for activity of aequorin by taking 100 ML 
of each fraction, then adding 3 ML of 2.36><10_4 M coelentera 
Zine and measuring the intensity of light emitted as described 
before. The fractions shoWing activity Were combined and 
lyophiliZed. The lyophiliZed conjugates Were resuspended in 
30 mM Tris-HCl buffer, pH 7.0, containing 2 mM EDTA, 
0.15 M NaCl and 1 mg/mL BSA (assay buffer) and stored in 
aliquots at —80° C. 
Calibration curves Were generated for each of the conju 
gates (1:50, 1:200, 1:500) by ?rst converting the apoaequorin 
conjugate to aequorin With coelenteraZine as described 
before. Standard solutions Were prepared by serially diluting 
the stock solutions of the conjugates assay buffer. A volume 
of 100 ML of these solutions Was placed in a microtiter plate 
and the luminescence activity of aequorin Was measured. The 
luminescence signal Was integrated over a 3 second time 
period. All points Were obtained in triplicates. 
For the binder dilution studies aliquots of 100 ML of differ 
ent concentrations of serially diluted anti-6-keto-PGF1OL anti 
body, produced in sheep and 50 ML of 1x10‘10 M 6-keto 
PGFla-aequorin conjugate Were placed simultaneously in 
microtiter plates pre-coated With a secondary antibody, don 
key anti-sheep lgG. All dilutions Were done in the assay 
buffer. The plates Were incubated in dark at room temperature 
for 2 h With shaking at 300 rpm. Then the plates Were Washed 
With Wash buffer (30 mM Tris-HCL buffer, pH 7.0, contain 
ing 2 mM EDTA, 0.15 M NaCl, and 0.1% TWeen 20) three 
times to remove any unbound primary antibody or any 
unbound conjugate. Finally, the light intensity Was measured 
as described earlier for the calibration plot. 
Dose-Response Curve: A dose-response curve Was generated 
for 6-keto-PGFla by simultaneously incubating 100 ML of 
6-keto-PGF1a antibody (1:10,000 dilution), 50 ML of differ 
ent concentrations of the serially diluted analyte, 6-keto 
PGF la, and 50 ML of 1 x10“10 M coelenteraZine bound 6-keto 
PGFla-aequorin conjugate (1 :500) on microtiter plates 
coated With the secondary antibody. The plate Was incubated 
in dark at room temperature for tWo hours With shaking at 300 
rpm. The plate Was Washed three times With the Wash buffer to 
remove any unbound components. The light intensity Was 
measured as described before. 
A dose-response curve for 6-keto-PGF1a in plasma Was 
generated by preparing serially diluted standard solutions of 
6-keto-PGF1a in human plasma (previously diluted 1:200 
times With deioniZed Water) and adding them simultaneously 
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With 6-keto-PGFla-aequorin conjugate and the 6-keto 
PGF la antibody to the Wells With the immobilized secondary 
antibody. The incubation and Washing steps Were performed 
in the same manner as previously described in the generation 
of dose-response curve. The bioluminescence Was triggered 
and measured as described before. 
EXAMPLE 2 
Construction of Plasmids containing Aequorin Mutants. The 
gene of a mutant apoaequorin in Which all three cysteines of 
the native aequorin Were replaced by serines Was used as a 
template for the PCR. A unique mutation Was introduced on 
the puri?ed apoaequorin gene (Ala 69 to cysteine 69) by 
employing PCR site-directed mutagenesis. The oligonucle 
otides used for PCR are AQ69-1 and AQ69-2 (see Table 1). 
The folloWing tWo primers Were used as outside primers to 
introduce the restriction endonuclease site for Hind Ill and 
Sal I restriction enZymes: 
1) TCTTCTTCTTCTTCTAAGCTTGTCAAGCTTACA 
TCAGACTTCGACAACCCAAGA (SEQ ID NO. 1); and 2) 
AGAAGAAGMGAGTCGACCAGATCTGG 
TACCCGGGAATT (SEQ ID NO. 2). 
The DNA obtained by PCR and the vector PFLAG-ATS 
Which consists of the gene sequence for the octapeptide 
upstream of the multiple cloning site (MCS) Were digested 
With the restriction enZymes Hind Ill and Sal 1. Next, the 
digested DNA fragment Was ligated into the plasmid pFLAG 
ATS, to yield the pSD1004 vector. The apoaequorin mutants 
containing unique cysteine residues at position 70, 74 and 76 
Were prepared in the same manner (see Table 1) as described 
above. DNA sequencing Was performed at the Macromolecu 
lar Center (University of Kentucky) to con?rm the presence 
site-speci?c mutations. 
Expression and Isolation of Aequorin Mutants. For expres 
sion of apoaequorin mutant 69 the plasmid pSD 1004 Was 
transformed into Bacteria (E. coli, strain JM109). A 2 mL 
volume of LB broth containing 100 ug/mL of ampicillin Was 
inoculated With a colony of bacteria containing plasmid pSD 
1004. The cells Were groWn for 17 h at 37° C. in an aerated 
shaker. The cell culture Was transferred to 400 mL LB broth 
containing 100 ug/mL ampicillin, and alloWed to groW until it 
reached an absorbance of 0.6 at 600 nm. For induction of 
protein expression, 1 M IPTG stock solution Was added such 
that the ?nal IPTG concentration in the culture Was 1.0 mM. 
The culture Was alloWed to groW for an additional 4.0 h at 37° 
C. in the shaker. The cells Were centrifuged for 30 min at 27° 
C. and pelleted. 
The apoaequorin mutant 69 thus expressed Was released 
from the periplasm using an osmotic shock procedure. The 
pellets Were ?rst resuspended in 40 mL of 10 mM Tris-HCl/ 
30 mM NaCl, pH 7.5. The cells Were then collected by cen 
trifuging for 15 min at 27° C., and Were resuspended in 40 mL 
of 33 mM Tris-HCl, pH 7.5. The centrifugation and resuspen 
sion steps Were repeated, but this time the cells Were resus 
pended vigorously With 40 mL Stage 1 buffer. The resus 
pended cells Were incubated at 37° C. for 10 min, With sloW 
shaking. The cells Were again collected by centrifuging for 10 
min at 27° C. The pellets Were ?nally resuspended rapidly 
With vigorous shaking for 10-15 min in 80 mL of chilled 
deionized-distilled Water. After centrifuging for 10 min at 4° 
C., the supernatant Was collected and lyophiliZed. The lyo 
philiZed sample Was dissolved in deioniZed Water and dia 
lyZed three times against 30 mM Tris-HCl, pH 7.7, buffer 
containing 0.15 M sodium chloride, 2 mM EDTA, and 4 mM 
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DTT. The dialyZed sample Was then centrifuged for 10 min at 
4° C. to remove any cell membrane fragments. The superna 
tant, Which consisted of unpuri?ed protein Was ?ltered With a 
0.2 pm syringe ?lter and Was immediately puri?ed. The 
apoaequorin mutants 70, 74 and 76 Were expressed and iso 
lated in the same Way as described above by using bacteria 
containing plasmid pSD 1005, pSD 1006 and pSD 1007 
respectively. 
Puri?cation of the Apoaequorin Mutants. The proteins Were 
puri?ed by using an anti-octapeptide M2 agarose a?inity 
column. The column Was equilibrated With 50 mM Tris-HCl, 
pH 7.4 containing 150 mM NaCl and 2 mM EDTA (TBS 
buffer). The solution containing protein Was loaded on the 
column and the column Was Washed three times With 15 mL 
of TBS buffer. The proteins Were eluted using 1 mL aliquots 
of 0.1 M glycine, pH 3.0, into tubes containing TBS buffer. 
The fractions containing the protein and their purity Was 
determined by SDS-PAGE using 12.5% polyacrylamide gels, 
Which Were developed by silver staining (Pharmacia Biotech, 
Uppsala, SWeden). Fractions containing the fusion protein 
Were pooled together and glucose Was added to a ?nal con 
centration of 30 mM folloWed by lyophiliZation. The lyo 
philiZed protein Was resuspended in deioniZed distilled Water. 
Excess salt Was removed by dialyZing tWice against 30 mM 
Tris-HCl, pH 7.4 containing 2 mM EDTA and 2 mM DTT. 
The protein concentration Was determined by using the Brad 
ford protein assay, With BSA as the standard. 
Conversion of Apoaequorin Mutants to Photoproteins. A set 
amount of puri?ed protein in 30 mM Tris-HCl, pH 7.4, buffer 
containing 2 mM EDTA and 2 mM DTT Was mixed With a 
three time molar excess of coelenteraZine in a glass tube. The 
mixture Was brie?y vortexed and then placed on ice for the 
required time. 
Bioluminescence Emission Study. A volume of 10 pL of the 
mutant proteins at a concentration of 1 ug/mL Was added to a 
glass tube, and the bioluminescence Was measured by inject 
ing 100 pL of luminescence triggering buffer (100 mM Tris 
HCl, 100 mM CaCl2, pH 7.5). The bioluminescence signal 
Was collected at 0.1 second intervals over a 4 second time 
period. 
Bioluminescence Emission Spectra ofApoaequorin Mutants. 
Luminescence Was triggered by careful addition of 1 .0 mL of 
a 1.0><10—6 M solution of mutant aequorin using a constant 
rate syringe pump into 0.5 mL of luminescence triggering 
buffer. Emission spectra Were obtained using a Fluorolog-2 
spectro?uorometer from Spex Industries (Edision, NJ.) 
without turning on lamp or chopper. The spectra Were not 
corrected for changes in sensitivity of the photomultiplier 
tube to luminescence at different Wavelengths. 
Conjugation of Aequorin Mutant to Analyte: A volume of 1 
mL of 1x10‘6 M. aequorin Was alloWed to incubate With 
coelenteraZine for 3 h at 4° C. Five-fold excess of a maleim 
ide/iodoacetamide derivative of analyte Was alloWed to react 
With mutant aequorin for 2 h at RT. The conjugates Were 
passed through a siZe exclusion column in order to remove 
any unconjugated maleimide/iodoacetamide derivative of 
analyte. The fractions Were tested for activity of aequorin by 
taking 100 pL of each fraction, then adding 3 pL of 2.36><10_4 
M coelenteraZine and measuring the intensity of light emitted 
as described before. The fractions shoWing activity Were 
combined and lyophiliZed. The lyophiliZed conjugates Were 
resuspended in 30 mM Tris-HCl buffer, pH 7.0, containing 2 
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mM EDTA, 0.15 M NaCl and 1 mg/mL BSA (assay buffer) 
and stored in aliquots at —80° C. 
EXAMPLE 3 
A comparative study betWeen analysis of 6-keto-PGF1a 
With and Without extraction from plasma Was carried out. In 
order to extract 6-keto-PGF la from plasma, a ?xed volume of 
the plasma sample Was ?rst acidi?ed With 2M HCl to pH 3.5. 
The sample Was alloWed to stand for 15 min at 4° C., after 
Which it Was centrifuged for 2 min to remove any precipitate. 
MeanWhile, a C 1 S-reverse phase column Was Washed With 10 
mL ethanol, folloWed by 10 mL deioniZed Water. The sample 
Was then applied under a slight positive pressure to obtain a 
How rate of 0.5 mL/min. The column Was Washed With 10 mL 
of Water, folloWed by 10 mL of 15% ethanol and ?nally 10 mL 
of hexane. The sample Was eluted using 10 mL of ethyl 
acetate. Elution Was carried out at a How rate of 2 mL/min. 
The ethyl acetate in the samples Was evaporated under a 
stream of nitrogen. The dried samples Were ?rst dissolved in 
50 pL ethanol, and then in the same volume of the assay buffer 
as that of the plasma sample initially used for extraction. 
These samples Were used in the dose response curve per 
formed in buffer. 
The analysis of 6-keto-PGF1a directly in plasma Without 
extraction Was performed by diluting the samples 1:200 times 
and using 50 pL in the dose-response curve along With 100 pL 
6-keto-PGF1a of antibody and 50 pL of 6-keto-PGFla-ae 
quorin conjugate. The analysis Was performed in the same 
manner as the dose-response curve described before. The 
amount of 6-keto-PGFla in the samples Was calculated from 
the standard dose response curve generated in plasma. The 
appropriate dilution factor Was taken into consideration When 
calculating the amount of 6-keto-PGFla present in each 
sample. 
For in vivo analysis plasma samples Were obtained from 
?ve patients With severe pulmonary arterial hypertension and 
7 normal controls. Written informed consent Was obtained 
from all patients; the protocol Was approved by the Institu 
tional RevieW Board at Mount Sinai School of Medicine. Of 
the ?ve patients, three Were on chronic intravenous prostacy 
clin. All patient samples Were analyZed in the same manner as 
the dose response curve in plasma. The samples Were diluted 
1:200 times to minimiZe matrix effects and 50 pL of the 
sample Was used in the assay. The amount of 6-keto-PGF la in 
the samples Was calculated as described before for sample 
analysis Without extraction. All plasma samples Were 
obtained and stored froZen at —20° C., in aliquots until use. 
In order to obtain recovery data further analysis of the 
samples Was performed. TWo of the normal plasma samples 
and tWo patient plasma samples Were ?rst analyZed using the 
assay Without extraction. Then the normal samples Were 
spiked With 5 pg/mL of6-keto-PGF1a and the patient samples 
Were spiked With 10 pg/mL of 6-keto-PGFla and the samples 
Were used once again in the assay. In each case the samples 
Were diluted 1:200 times to minimiZe matrix effects and 50 
pL of the sample Was used in the assay. The amount of 
6-keto-PGF1a in the samples Was calculated as described 
before for sample analysis Without extraction. The samples 
Were analyZed in triplicates. 
The plasmid containing the cysteine free mutant of 
aequorin Was previously constructed in our laboratory. LeWis, 
J. C., LopeZ-Moya, J. 1., and Daunert S. Bioconjugale Chem. 
2000, 11, 65-70. The cysteine free mutant of aequorin Was 
chosen for the development of this assay because it shoWed 
enhanced activity as compared to Wild-type aequorin. The 
cysteine free mutant of aequorin Was expressed from plasmid 
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pSD110. Puri?cation of aequorin Was carried out using an 
HQH anion exchange column. The fractions containing 
bioluminescence activity Were lyophilized With glucose and 
later resuspended in deionized Water. SDS-PAGE analysis 
Was carried out to check the ef?ciency of puri?cation. A 
single band Was observed at ~20 kDa in the lyophilized frac 
tion for pure aequorin. The yield of the protein Was found to 
be 1.8 mg/L of culture. 
Before conjugating 6-keto-PGFla to aequorin, the lyo 
philized fraction Was dialyzed against bicarbonate buffer to 
remove any residual Tris-HCl salt, Which might interfere With 
the conjugation. The dialyzed aequorin Was then charged With 
3 times molar excess of coelenterazine so that the analyte 
Would not conjugate in the coelenterazine binding site, Which 
might cause loss in activity of aequorin. 
The conjugation method used involved a tWo-step coupling 
method using EDC (1-Ethyl-3-(Dimethylaminopropyl) car 
bodiimide hydrochloride) and sulfo NHS, Which is a Water 
soluble analog of NHS (N -hydroxy succinimide). EDC, a 
dehydrating agent, reacts With the carboxyl group of 6-keto 
PGF la, and forms an amine-reactive unstable, O-acylisourea 
intermediate of 6-keto-PGFla. NHS reacts With the O-acyli 
sourea-intermediate to form an NHS ester to stabilize this 
intermediate. The NHS ester then reacts With the amine 
groups on aequorin. The advantage of the tWo-step procedure 
is the prevention of the modi?cation of the protein carboxyl 
groups due to exposure to EDC. Grabarek, Z. a. G., J. Anal. 
Biochem. 1990, 185. The reaction is quenched by a thiol 
containing compound like [3-mercaptoethanol. Three differ 
ent conjugates Were prepared (1 :50, 1:200, 1:500) using this 
method, by increasing the initial molar concentration of the 
NHS ester of 6-keto-PGF1OL While keeping the concentration 
of aequorin constant. The conjugates Were passed through a 
size exclusion column to remove any unconjugated ester of 
6-keto-PGF1a and unreacted [3-mercaptoethanol. They Were 
then lyophilized and later resuspended in the assay buffer. 
In order to study the effect of conjugation on the biolumi 
nescence activity of aequorin and to select an appropriate 
conjugate concentration for the assay, calibration plots Were 
constructed for each of the conjugates (data not shoWn). The 
conjugates (1:50, 1:200 and 1:500) could be detected doWn to 
1x10‘12 M. A concentration of 1x10‘10 M of the three con 
jugates Was selected for the binder dilution study. This con 
centration Was loW enough to be able to detect aequorin at loW 
levels With high sensitivity and at the same time it shoWed 
much higher activity than the background. 
The next step Was to study the interaction betWeen the 
anti-6-keto-PGFla antibody and the conjugates. For this, 
binder-dilution curves Were generated for all three conjugates 
as shoWn in FIG. 1. The 6-keto-PGFla antibody Was incu 
bated With a concentration of 1x10“10 M of the conjugates in 
the secondary antibody-coated microtiterplate for 2 h at room 
temperature. After Washing the plate to remove any unbound 
antibody or conjugate the luminescence Was measured. As the 
concentration of antibody increased the light intensity 
increased until it reached a concentration after Which there 
Was no signi?cant increase. It Was observed that the 1:500 
conjugate shoWed maximum binding therefore, it Was used 
for the remaining experiments in the assay. The amount of 
antibody to be used in the assay Was selected such that the 
light intensity emitted is suf?cient to measure a signal above 
the background, While keeping the amount of available bind 
ing sites to a minimum. The antibody dilution selected for 
developing the assay Was 1:10,000 dilution. The effect of 
increased or decreased amounts of 6-keto-PGF1a antibody 
and/ or conjugate on the dose-response curve Was also evalu 
ated. In the ?rst tWo cases, the conjugate concentration Was 
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kept constant at 1x 1 0'10 M, Whereas the antibody concentra 
tion Was either increased or decreased by a factor of 5. In the 
third experiment, the antibody concentration used Was a 1 :10, 
000 dilution, and the conjugate concentration Was increased 
to 1x10‘9 M. As shoWn in FIG. 2, When a higher antibody 
concentration is used, the sensitivity improves but the detec 
tion limit is compromised. When a more diluted amount of 
antibody is used, the dynamic range narroWs signi?cantly and 
the sensitivity is reduced. Finally, When a higher concentra 
tion of the conjugate is employed both, the detection limit and 
the dynamic range Worsen. Therefore, based on these data, 
the optimum antibody dilution for the assay Was determined 
to be 1:10,000 and the conjugate concentration to be 1><10_l0 
M (FIG. 2). Next, a dose-response curve Was generated by 
simultaneously mixing varying concentrations of free 6-keto 
PGFlot, 1><10_lo M of the 1:500 conjugate, and 1:10,000 
dilution of the 6-keto-PGF10t antibody and incubating them 
in microtiter plates immobilized With the secondary antibody. 
The dose-response curve obtained for 6-keto-PGF10t as 
depicted in FIG. 3, is sigmoidal in shape, With the lumines 
cence intensity being loWer at high concentrations of 6-keto 
PGFIO. and increasing as the concentration of 6-keto-PGF10t 
decreases. The Working range of the curve ranges for concen 
trations of 10,000 pg/mL-l pg/mL. The detection limit for 
6-keto-PGF10t Was determined to be 1 pg/mL, Which corre 
sponds to a 2x10‘12 M concentration of 6-keto-PGF10t. 
Since the goal Was to detect 6-keto-PGF10t in plasma, it 
Was necessary to validate this assay in plasma and to study 
any possible matrix effects on the performance of the conju 
gate or the binding capabilities of the 6-keto-PGF1a antibody 
in plasma. The assay Was, therefore, performed in 1:200 
diluted human plasma spiked With known concentrations of 
6-keto-PGFla. The dose-response curve obtained (FIG. 4) 
Was almost identical to that obtained for 6-keto-PGFla in 
buffer. According to this dose response curve, and as expected 
of 6-keto-PGF la at high concentrations of free 6-keto-PGF1a 
most of the binding sites are occupied by 6-keto-PGFlw and 
therefore, a loW bioluminescence signal in the solid phase Was 
obtained. As the concentration of free-analyte decreases, the 
bioluminescence intensity reaches a maximum since most of 
the binding sites on the antibody are occupied by the conju 
gate. The detection limit of this dose-response curve Was also 
found to be 1 pg/mL and the limit of quantitation Was found 
to be 5.11 pg/mL. This demonstrates that even loW levels of 
6-keto-PGF1a could be detected in the assay, and also that 
aequorin is an excellent label for the detection of biomol 
ecules in biological ?uids. 
The inter-assay precision Was determined by generating 
the do se-response curve in plasma for ?ve consecutive days in 
exactly the same manner as described earlier. The percent 
coel?cient of variation for samples containing different con 
centrations of 6-keto-PGFlw Was calculated. The average 
coel?cient of variation Was found to be 4.5%. The intra-assay 
precision Was determined by doing 4 replicate measurements 
of the same sample. The average coel?cient of variation Was 
found to be 1.25%. 
Presence of various prostaglandins other than 6-keto 
PGFla in the blood can cause non-speci?c binding With the 
6-keto-PGF1a antibody and interfere With the detection of 
6-keto-PGFlw giving extremely high values of 6-keto 
PGFla. Therefore, it becomes important to con?rm that the 
amount of 6-keto-PGF la obtained from our assay is only due 
to 6-keto-PGF1a and no other prostaglandin. The cross-reac 
tivities of other prostaglandins similar in structure to 6-keto 
PGFla Were determined by preparing standard solutions of 
the compounds in the assay buffer ranging from 100,000 to 
100 pg/mL and using them in this assay for 6-keto-PGFla. 
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The measured 6-keto-PGFla concentration at 50% B/BO Was 
then calculated. The percent cross-reactivities Were calcu 
lated by comparison of measured cross-reactant concentra 
tion and the actual concentration (known amount) of the 
cross-reactant in the sample (Table 1). It must be noted that 
the pro staglandins occur at different times in the arachidonic 
acid pathWay and in different concentrations. Also, 2,3 -dinor 
6-keto-Prostaglandin F la is found in urine and does not occur 
in plasma, hoWever since it is the immediate metabolite of 
6-keto-PGF1a We decided to analyze the cross-reactivity of 
2,3-dinor-6-keto-Prostaglandin F la as Well. From the table it 
is clear that the prostaglandins do not shoW any signi?cant 
amount of cross-reactivity. This indicates that the assay is 
speci?c only for 6-keto-PGF1a and there is no interference 
from other prostaglandins, Which might be present in the 
plasma samples. The assay can, therefore, be used to measure 
6-keto-PGF1a directly from plasma. 
TABLE 1 
Oligonucleotide sequence of primers 
AQ69-1 GCCTTCTTCGGAGGAEGGAATGAAATAT Ala69-Cys69 
(SEQ ID NO. 3) 
AQ69-2 ATATTTCATTCC?TCCTCCGAAGAAGGC Ala69-Cys69 
(SEQ ID NO. 4) 
AQ70-1 GCTEATGAAATATGGTGTGGAAACTGAT Gly70-Cys70 
(SEQ ID NO. 5) 
AQ70-2 ATCAGTTTCCACACCATATTTCAT?AGC Gly70-Cys70 
(SEQ ID NO.6) 
AQ74-1 GCTGGAATGAAATATTGEGGAAACTGAT Gly74-Cys74 
(SEQ ID NO. 7) 
AQ74-2 ATCAGTTTCCAC?ATATTTCATTCCAGC Gly74-Cys74 
(SEQ ID NO. 8) 
AQ76-1 ATGAAATATGGTGTGEACTGATTGGCCT Glu76-Cys76 
(SEQ ID NO. 9) 
AQ76-2 AGGCCAATCAGT?CACACCATATTTCAT Glu76-Cys76 
(SEQ ID NO. 10) 
EXAMPLE 3 
Cross-reactivities of related prostaglandins Were measured 
by using varying concentrations of 50 ML of the cross reactant 
in the dose response curve instead of 6-keto-PGF10L. The 
percent cross-reactivities Were calculated at 50% B/BO. The 
results are shoWn in Table 2. 
TABLE 2 
Average Standard 
Analyte Percent Bound Deviation 
6-keto-Prostaglandin F1 100% 1.71 
Prostaglandin 131 5.4% 4.65 
Prostaglandin F2 3.41% 3.21 
13,14-dihydroxy-15-keto- 0.45% 1.01 
Prostaglandin F1 
2,3-dinor-6-keto-Prostaglandin P1 10.1% 5.78 
Prostaglandin D2 7.75% 2.11 
Prostaglandin E1 6.75% 3.87 
6,15-diketo-13,14-dihydro- 1.83% 0.92 
Prostaglandin F 1 
EXAMPLE 4 
In vivo sample analysis Was performed With the present 
assay. The PPH patients and control samples Were provided 
by Dr. Michael Poon of the Mount Sinai Pulmonary Hyper 
tension Program. Five PPH patient plasma samples Were 
diluted (1:200) times With buffer and used directly in the 
assay. The concentration of 6-keto-PGF1a in the samples Was 
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measured using the standard dose response curve obtained in 
plasma by diluting plasma of a normal subject (1:200) to 
measure the amount of 6-keto-PGFla. It Was observed that 
the levels of 6-keto-PGF1a increased With increase in the 
pro stacyclin dose. Three normal control samples Were used to 
produce the standard dose-response curves, and the curves 
Were found to be similar. The values of 6-keto-PGF1a in the 
samples of patients obtained With each of the standard curves 
Were also similar. Table 2 shoWs the 6-keto-PGF1a values in 
normal and patients samples in vivo. Plasma samples of the 
normal subjects Were used to produce standard dose-response 
curves and values of 6-keto-PGF1a in patient samples Were 
obtained using those curves. The measurements Were per 
formed in triplicates. The results are shoWn in Table 3. 
TABLE 3 
6-keto-Prostaglandin F1 
concentration measured 
Prostacyclin Dose Without extraction Standard 
Plasma Sample (ngkg/min) (ng/ml) Deviation 
Average of3 i 1.7 0.01 
normal samples 
PPH Patient 1 28.5 9.9 0.2 
PPH Patient 2 10 6.7 0.05 
PPH Patient 3 8 4.1 3.1 
PPH Patient 4 0 2.2 1.5 
PPH Patient 5 0 1.5 0.05 
EXAMPLE 5 
In order to verify the concentration of 6-keto-PGF1a 
obtained from plasma using the assay of the present inven 
tion, 6-keto-PGF1a Was extracted from the plasma samples of 
7 normal subjects and the 5 PPH patients using the C 18-Sep 
Pak columns, and these values Were compared With the values 
obtained When plasma samples Were used directly in our 
assay Without extraction. In the extraction method, the 
6-keto-PGF1a Was obtained in the ethyl acetate fraction. All 
ethyl acetate Was evaporated under N2 and the dried 6-keto 
PGFla Was dissolved ?rst in ethanol folloWed by the assay 
buffer. This 6-keto-PGF1a Was used in the assay performed in 
buffer. The concentrations of 6-keto-PGF1a obtained using 
the aequorin assay in plasma samples, Without pretreatment 
Were observed to be highly correlated With the measured 
6-keto-PGF1a after extraction. The equation for the straight 
line can be given as y:0.79x+418, r:0.988, n:12. 
Further in vivo analysis Was performed in order to deter 
mine the recovery of 6-keto-PGF1a from samples using this 
assay. TWo of the normal plasma samples and tWo patient 
plasma samples Were ?rst analyZed using the assay as 
described before and determining the concentration of 
6-keto-PGF1a present in the samples by using the standard 
curve in 1:200 diluted plasma. A knoWn amount of 6-keto 
PGFla Was spiked into the samples and the samples Were 
analyZed once again to determine the concentration of 6-keto 
PGFla. Percent recovery data Were obtained using the con 
centration of 6-keto-PGF1a in unspiked samples and the con 
centration obtained after spiking. It is clear from the data 
(Table 3) that this assay for 6-keto-PGFla gives recoveries 
Within the range error. Percent recovery data of normal 
samples and patient samples are shoWn in Table 4. The mea 
surements Were performed in triplicate. 
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TABLE 4 
Concentration of Amount of Concentration of 
6-keto-PGF 1 6-keto-PGF 1 6-keto-PGFl 
Prostacyclin found in unspiked spiked into found in spiked 
Dose Weight samples salnples salnples Percent 
Subject (ngkg/min) (kg) (ngml) (ngml) (ng/ml) Recovery 
Norrnal salnple 0 i 2.05 5 7.53 106.8% 
Norrnal salnple 0 i 2.91 5 8.01 109% 
PPH patientl 10 95 8.32 10 20.2 115% 
PPH patient2 28.5 78.5 9.96 10 21.7 117.4% 
In conclusion, this immunoassay, is the ?rst direct assaying 
technique for quanti?cation of plasma 6-keto-PGF1a Without 
the process of extraction. The 6-keto-PGF1a concentrations 
obtained from patient samples by extraction and Without 
extraction shoW good correlation. In addition, the antibody 
employed for the assay, and hence the assay itself, does not 
shoW signi?cant binding to other related prostaglandins. 
Therefore, the possibility of obtaining falsely high values of 
6-keto-PGF1a due to the presence of other similar prostag 
landins is eliminated. The assay has a Wide Working range, 
and a loW detection limit of 1 pg/mL, Which enables the 
measurement of the creation of distribution curves of plasma 
prostacyclin levels in normal and disease states. This assay 
also characterizes the application of aequorin in quanti?ca 
tion of important components present in the body by directly 
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measuring them in the biological matrix Without requiring 
any pre-treatment of the biological ?uids. This assay may 
alloW high throughput analysis of the levels of plasma pros 
tacyclin in patients With primary pulmonary hypertension and 
the clinical implications of various levels of plasma prosta 
cyclin in the pathogenesis and clinical management of this 
devastating disease. 
The following abbreviations are used herein: 6-keto 
PGFla: 6-keto-ProstaglandinFla; PPH: Primary Pulmonary 
Hypertension; EDC: 1-Ethyl-3-(Dimethylaminopropyl) car 
bodiimide hydrochloride; NHS: N-hydroxysuccinimide; 
BSA: Bovine plasma albumin; SDS-PAGE: Sodium dodecyl 
sulfate-Polyacrylamide gel electrophoresis; Tris: Tris (hy 
droxymethyl)amino methane; EDTA: ethylenediaminetet 
raacetic acid. 
SEQUENCE LISTING 
SEQ ID NO 1 
LENGTH: 54 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Artificial sequence of unknown origin used as 
outside primers to introduce the restriction endonuclease site for 
Hind III and Sal I restriction enzymes 
<400> SEQUENCE: l 
tcttcttctt cttctaagct tgtcaagctt acatcagact tcgacaaccc aaga 
SEQ ID NO 2 
LENGTH: 39 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
54 
OTHER INFORMATION: Artificial sequence of unknown origin used as 
outside primers to introduce the restriction endonuclease site for 
Hind III and Sal I restriction enzymes 
<400> SEQUENCE: 2 
agaagaagaa gagtcgacca gatctggtac ccgggaatt 
SEQ ID NO 3 
LENGTH: 30 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
PCR 
<400> SEQUENCE: 3 
39 
OTHER INFORMATION: Artificial sequence of unknown origin used for 
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—cont inued 
gccttcttcg gaggatgtgg aatgaaatat 3O 
<2ll> LENGTH: 30 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Artificial sequence of unknown origin used for 
PCR 
<400> SEQUENCE: 4 
atatttcatt ccacatcctc cgaagaaggc 3O 
<2ll> LENGTH: 30 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Artificial sequence of unknown origin 
<400> SEQUENCE: 5 
gcttgcatga aatatggtgt ggaaactgat 3O 
<2ll> LENGTH: 30 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Artificial sequence of unknown origin 
<400> SEQUENCE: 6 
atcagtttcc acaccatatt tcatgcaagc 3O 
<2ll> LENGTH: 30 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Artificial sequence of unknown origin 
<400> SEQUENCE: '7 
gctggaatga aatattgtgt ggaaactgat 3O 
<2ll> LENGTH: 30 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Artificial sequence of unknown origin 
<400> SEQUENCE: 8 
atcagtttcc acacaatatt tcattccagc 3O 
<2ll> LENGTH: 30 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Artificial sequence of unknown origin 
<400> SEQUENCE: 9 
atgaaatatg gtgtgtgcac tgattggcct 3O 
<2lO> SEQ ID NO 10 
<2ll> LENGTH: 30 
<2l2> TYPE: DNA 
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—cont inued 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Artificial sequence of unknown origin 
<400> SEQUENCE: lO 
aggccaatca gtgcacacac catatttcat 30 
What is claimed is: 
1. A method of determining amount of prostaglandin in a 
plasma sample comprising: 
(1) providing a plasma sample from a patient in contact 
With a surface coated With an anti-immunoglobulin anti 
body; 
(2) incubating the plasma sample With an effective amount 
of an anti-6-keto-prostaglandin Fla (6-keto-PGFla) 
antibody, Wherein the anti-immunoglobulin antibody 
binds to the anti-6-keto-PGFlot-antibody, and With a 
conjugate comprising 6-keto-PGF1a covalently bound 
to an aequorin mutant, 
Wherein said aequorin mutant comprises serine substitu 
tions for all three cysteine residues as present in Wild 
type aequorin (Cys—>Ser), Wherein said aequorin 
mutant further comprises a single cysteine residue sub 
stituted at amino acid position 69 (Ala69 QCys), 70 
(Gly70 QCys), 74 (Gly74 aCys) or 76 (Glu76 QCys), 
and 
Wherein the 6-keto-PGF1a is coupled to the aequorin 
mutant via reaction With the sulihydryl group of the 
single cysteine; 
(3) removing any unbound anti-6-keto-PGFlot-antibody 
and said conjugate following incubation; 
(4) measuring light intensity of the 6-keto-PGF1a conju 
gate bound to the anti-immunoglobulin antibody; and 
15 
20 
25 
30 
35 
(5) correlating the light intensity of the bound 6-keto 
PGFIOL conjugate With the amount of the prostaglandin 
in the plasma sample. 
2. The method of claim 1 Wherein the amount of the pros 
taglandin in the sample is correlated With prostacyclin 
amount in the sample. 
3. The method of claim 1 Wherein the plasma sample is 
obtained from a patient receiving intravenous prostaglandin 
therapy. 
4. The method of claim 1 Wherein concentration of said 
conjugate in the assay is about l><l0_lo M. 
5. A kit for measuring prostacyclin in plasma comprising: 
(1) an anti-6-keto-prostaglandin Fla (6-keto-PGFla) anti 
body; 
(2) an anti-immunoglobulin antibody that binds to the anti 
6-keto-PGF lot-antibody; and 
(3) a conjugate comprising 6-keto-PGF1a covalently 
bound to an aequorin mutant; 
Wherein said aequorin mutant comprises serine substitu 
tions for all three cysteine residues as present in Wild 
type aequorin (CysQSer), Wherein said aequorin 
mutant further comprises a single cysteine residue sub 
stituted at amino acid position 69 (Ala69QCys), 70 
(Gly70 QCys), 74(Gly74QCys) or 76 (Glu76—>Cys), 
and Wherein the 6-keto-PGFla is coupled to the 
aequorin mutant via reaction With the sulihydryl group 
of the single cysteine. 
* * * * * 
